June 11 (Reuters) – Novartis said on Thursday an experimental drug, which it ‌acquired as part of its $12 ‌billion takeover of Avidity, showed promise in an ​early-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.

• The Swiss drugmaker ‌said the ⁠drug, known as del-brax, lowered two blood markers linked to the ⁠disease and showed reduced signs of muscle damage in patients with facioscapulohumeral ​muscular dystrophy.

• ​Novartis said the ​drug shows potential ‌to become the first disease-modifying treatment for FSHD, which can cause weakness in the face, shoulders, arms and other muscles.

• The company estimates it affects about ‌45,000 to 87,000 people ​in the U.S. ​and EU.

• The ​drug’s safety profile was ‌consistent with previous results, the ​company said.

• ​Novartis plans to discuss the data with health regulators around the ​world, while ‌a late-stage study of the drug ​is currently enrolling patients.

(Reporting by Kunal ​Das in Bengaluru)